Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.36 |
| ▸ | MC3R | P41968 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
| ▸ | AKT1S1 | Q96B36 | 1/20 | 0.31 |
| ▸ | MARS1 | P56192 | 1/20 | 0.30 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.30 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25912112 | 0.94 | TMPRSS2 (0.35) | TMPRSS2MC3RAKT1AKT1S1 | |
| SCHEMBL25912130 | 0.94 | TMPRSS2 (0.37) | TMPRSS2MC3RAKT1AKT1S1GPR142 | |
| SCHEMBL25912170 | 0.92 | TMPRSS2 (0.35) | TMPRSS2MC3RAKT1AKT1S1 | |
| SCHEMBL24917181 | 0.92 | TMPRSS2 (0.36) | TMPRSS2MC3RAKT1AKT1S1 | |
| SCHEMBL25925879 | 0.90 | TMPRSS2 (0.35) | TMPRSS2MC3R | |
| SCHEMBL24789403 | 0.90 | TMPRSS2 (0.35) | TMPRSS2MC3RAKT1AKT1S1 | |
| SCHEMBL25925135 | 0.90 | TMPRSS2 (0.34) | TMPRSS2MC3RMARS1 | |
| SCHEMBL25912053 | 0.90 | TMPRSS2 (0.45) | TMPRSS2MC3RAKT1AKT1S1GPR142 | |
| SCHEMBL24917045 | 0.89 | TMPRSS2 (0.49) | TMPRSS2MC3R | |
| SCHEMBL24917333 | 0.88 | TMPRSS2 (0.35) | TMPRSS2MC3RAKT1AKT1S1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | VenatoRx Pharmaceuticals, Inc. (US) | 2023-05-02 | — | — | US | disclosed |
| US-20230024722-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230024722-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | SLC29A2, SLC29A1, PNP | TMPRSS2 100/4885MC3R 3923/4885AKT1 3331/4885 |
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | SLC29A2, SLC29A1, PNP | TMPRSS2 100/4885MC3R 3923/4885AKT1 3331/4885 |
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | SLC29A2, SLC29A1, PNP | TMPRSS2 100/4885MC3R 3923/4885AKT1 3331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.